1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
69569BC56F04EFE6B85258288006A5895
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/how-medical-affairs-creates-value-relationships-with-external-groups-payers?opendocument
18
19opendocument
2035.173.48.224
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Affairs Excellence

How Medical Affairs Creates Value & Relationships with External Groups: Payers

ID: 5507


Features:

13 Info Graphics

10 Data Graphics

200 Metrics


Pages/Slides: 31


Published: 2018


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "How Medical Affairs Creates Value & Relationships with External Groups: Payers"

STUDY OVERVIEW


Just like the pharmaceutical industry, Medical Affairs groups face a constantly evolving healthcare space. As a result, Medical Affairs leaders are continually adjusting what external groups they work with and how they work with them. And as payers have become dominant players in the critical access and reimbursement arena, Medical Affairs is now providing medical support as part of payer interactions.


But with payers a relatively new external group for Medical Affairs, organizations are still working out which functions and activities resonate best with managed care organizations. Best Practices, LLC performed this research study to probe Medical Affairs' roles, tools, effectiveness and success metrics in serving payer groups.

This study will help Medical Affairs leaders identify the tools, activities, services that peers are utilizing to interact with payers. It also provides key performance indicators and best practices to demonstrate value to payers.

KEY TOPICS

  • Executive Summary
  • Interactions with External Groups
  • Tools, Roles, Services, KPIs and Interactions Timeline: Payers
  • Benchmark Participant Demographics

SAMPLE KEY METRICS

  • What external groups does your Medical Affairs organization work with
  • How important are these external groups to your Medical Affairs organization
  • How effective is your Medical Affairs organization's work with these external groups
  • Which functions within your Medical Affairs organization have a role with payers
  • What tools does your Medical Affairs organization use to showcase value to payers
  • Rate the effectiveness of these tools used with payers
  • What are your key performance indicators for working with payers
  • What activities does your Medical Affairs organization conduct with payers

SAMPLE KEY FINDING

  • Payers rated as the most important external group. Despite a high importance of this group, MA struggles to effectively work with Payers.
  • 76% of respondents work with payers, 86% of those rated their work with payers very important but only 50% said their work is very effective.

METHODOLOGY

For this research, Best Practices, LLC engaged 50 Medical Affairs experts at 33 companies through a benchmarking survey. Research participants include Chief Medical Officer (CMO), VPs, Heads, Directors, Managers/Leaders and Specialists.


Industries Profiled:
Biotech; Chemical; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories; Communications


Companies Profiled:
Genentech; Boehringer Ingelheim; Novartis; EMD Serono; Bayer; Roche; Amgen; Novo Nordisk; Astellas; Shire; Abbott; Pfizer; Sanofi; Sandoz; Takeda Pharmaceuticals; Santen; Vifor Pharma; cipla; Siemens Healthcare; UCB Pharma; Roche Diagnostics; Teva Pharmaceutical Industries Ltd; Sanofi Genzyme; Jazz Pharmaceuticals; Janssen; Ferring Pharmaceuticals; Upsher-Smith; Seattle Genetics; Otonomy; CSL Behring; Sunovion; Tillotts Pharma; ApotheCom

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.